Get to know our clinical trials
Ensayo de Baxdrostat combinado con Dapagliflozina, comparado con Dapagliflozina sola en la progresión de Enferme sola en la progresión de Enfermedad Renal Crónica (ERC) en pacientes con ERC e hipertensión arterial.
TO LEARN MORE ABOUT THE BENEFITS AND SAFETY OF TREATMENT WITH AN INVESTIGATIONAL DRUG CALLED BAXDROSTAT IN COMBINATION WITH DAPAGLIFLOZIN IN PATIENTS WITH CKD AND HYPERTENSION AND ALSO TO BETTER UNDERSTAND THE DISEASE STUDIED AND ASSOCIATED HEALTH PROBLEMS.
Status
In recruitment
headquarters
Pamplona/Madrid
Technical Summary
- ENSAYO FASE III, ALEATORIZADO, DOBLE-CIEGO, DE GRUPOS PARALELOS Y CONTROLADO CON PRINCIPIO ACTIVO PARA EVALUAR LA EFICACIA, SEGURIDAD Y TOLERABILIDAD DE BAXDROSTAT COMBINADO CON DAPAGLIFLOZINA, COMPARADO CON DAPAGLIFLOZINA SOLA EN LA PROGRESIÓN DE ENFERMEDAD RENAL CRÓNICA (ERC) EN PACIENTES CON ERC E HIPERTENSIÓN ARTERIAL.
- Code EudraCT: 2023-506457-38
- Protocol number: D6972C00003
- Promoter: Astra Zeneca AB
- Molecule/Drug: Baxdrostat and dapagliflozin
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs